Girl loses High Court battle over NICE review of BioMarin’s ...

Pharma collaborates to improve chances of NICE backing Duche...

Project will initially focus on DMD but could benefit other rare diseases

Budget impact and cost effectiveness: alternatives to NICE a...

A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.

NICE and Highly Specialised Technologies: three years on

Leela Barham examines the process for the appraisal of Highly Specialised Technologies.

Funding rare disease treatments in the UK – navigating the l...

With the appraisal process for highly specialised treatments in the UK described by one NHS insider as 'impenetrable', and The MPS Society's (The Society for Mucopolysaccharide Diseases) recent